Podcasts about sglt2

A polygenic risk score significantly improved prostate cancer detection beyond PSA testing, identifying more treatable and aggressive cancers in high-risk men. New WHO guidelines aim to reduce global meningitis deaths by standardizing early diagnosis, treatment, and care across settings. GLP-1 receptor agonists and SGLT2 inhibitors were linked to reduced Alzheimer's risk, with GLP-1s showing the most consistent neuroprotective effects in recent studies. Lastly, breast cancer mortality was 47% higher among Black women living in disadvantaged neighborhoods, underscoring the impact of social determinants on survival.

In this Healthed lectue, cardiologist, Professor Andrew Sindone and endocrinologist, Dr Ted Wu discuss the importance of SGLT2 inhibitors for patients with type 2 diabetes and cardiovascular disease, and the ground-breaking evidence that has seen this class of drugs now be recommended as second-line T2D treatment after metformin, particularly for its cardiovascular benefits. Importantly, the experts will also explain recent PBS changes that have improved access to SGLT2 inhibitors as well as other practical considerations associated with these medications.See omnystudio.com/listener for privacy information.

This episode of Don't Miss a Beat, recorded at the American College of Cardiology (ACC) 2025 Annual Scientific Sessions, explores the evolving landscape of heart failure with preserved ejection fraction (HFpEF) treatment, focusing on the implementation of combination therapies. Hosts Steve Greene, MD, and Muthiah Vaduganathan, MD, MPH, discuss the transition from a previously limited treatment landscape to a new era with multiple proven therapeutic options. To open the episode, Greene argues in favor of rapid-sequence implementation of HFpEF therapies, drawing parallels to the established 4-pillar guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF). He highlights 3 key classes of medications—SGLT2 inhibitors, non-steroidal mineralocorticoid receptor antagonists (MRAs), and incretin-based therapies—as the foundation of HFpEF treatment. He emphasizes the importance of early and aggressive therapy initiation to maximize clinical benefits and reduce the risk of delayed or missed treatment opportunities among this population. Vaduganathan acknowledges the strength of the data supporting combination therapy but suggests a more risk-based approach, considering the broad clinical variability among HFpEF patients. He advocates for prioritizing rapid implementation in high-risk patients, such as those recently hospitalized, while allowing a more measured approach for lower-risk individuals. The discussion also touches on the role of phenotyping in tailoring treatment decisions, with GLP-1 receptor agonists being particularly relevant for patients with obesity and ARNi potentially benefiting those with mildly reduced ejection fraction. Looking ahead, the hosts preview upcoming trials, including CONFIDENCE and CONFIRMATION, which will evaluate combination therapy strategies in chronic kidney disease and HFpEF populations. They also discuss the potential of fixed-dose combination therapies to simplify implementation and improve adherence. The episode closes with both experts agreeing on the need for a structured, evidence-based approach to HFpEF treatment while emphasizing the importance of translating trial data into real-world practice. Relevant disclosures for Vaduganathan include Amgen, AstraZeneca, Bayer AG, Boehringer Ingelheim Pharmaceuticals, Cytokinetics, Lexicon, and others. Relevant disclosures for Greene include Amgen, AstraZeneca, Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Cytokinetics, and others. Chapters 00:00-Intro 02:30-Argument for Rapid Sequencing 05:32-Argument Against Rapid Sequencing 10:00-Argument for Risk-Based Sequencing 14:25-Pillars of GDMT in HFpEF

Listen in as our expert panel discusses which diabetes meds have cardiovascular (CV) benefits.  We'll review the evidence and discuss the pros and cons of SGLT2 inhibitors (dapagliflozin, empagliflozin, etc) and GLP-1 agonists (dulaglutide, semaglutide, etc) in patients with or at risk for CV disease.Special Guests:Lauren G. Pamulapati, PharmD, BCACPAssociate Professor, Ambulatory CareVirginia Commonwealth University School of PharmacyClinical Pharmacist, Hayes Willis Health Center/VCU HealthChristie Schumacher, PharmD, BCPS, BCACP, BCCP, BC-ADM, CDCES, FCCPProfessor, Pharmacy PracticeDirector, PGY2 Ambulatory Care Residency ProgramMidwestern University College of Pharmacy, Downers Grove CampusClinical Pharmacist, Northwestern MedicineTRC Editorial Advisory Board Participant:Stephen Carek, MD, CAQSM, DipABLMClinical Associate Professor of Family MedicinePrisma Health/USC-SOMG Family Medicine Residency ProgramUSC School of Medicine GreenvilleFor the purposes of disclosure, Dr. Schumacher reports a relevant financial relationship [CGM for diabetes management] with Abbott (speakers bureau).The other speakers have nothing to disclose. All relevant financial relationships have been mitigated.This podcast is an excerpt from one of TRC's monthly live CE webinars, the full webinar originally aired in February 2025.TRC Healthcare offers CE credit for this podcast. Log in to your Pharmacist's Letter, Pharmacy Technician's Letter,or Prescriber Insights account and look for the title of this podcast in the list of available CE courses.Claim CreditThe clinical resources mentioned during the podcast are part of a subscription to Pharmacist's Letter, Pharmacy Technician's Letter, and Prescriber Insights: Chart: Diabetes Medications: Cardiovascular and Kidney ImpactChart: Drugs for Type 2 Diabetes Algorithm: Stepwise Treatment of Type 2 DiabetesChart: Comparison of GLP-1 AgonistsToolbox: Improving Heart Failure CareSend us a textIf you're not yet a subscriber, find out more about our product offerings at trchealthcare.com. Follow, rate, and review this show in your favorite podcast app. Find the show on YouTube by searching for ‘TRC Healthcare' or clicking here. You can also reach out to provide feedback or make suggestions by emailing us at ContactUs@trchealthcare.com.

Qual é o risco de pacientes hospitalizados apresentarem infecção genitourinária por uso de inibidores do SGLT2?

Join us as we review recent practice-changing articles on suzetrigine for acute pain, the risk of PAD events from SGLT2 inhibitors, the safety of very low LDL, and the benefits of restrictive vs liberal transfusion strategies in acute MI with anemia. Fill your brain hole with a delicious stack of hotcakes! Featuring Rahul Ganatra (@rbganatra), Matt Watto (@doctorwatto), and special guest Molly Brett (Paul Williams got a break and took a much-needed vacation this week!). Claim CME for this episode at curbsiders.vcuhealth.org! Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Credits Written and Hosted by: Rahul Ganatra MD, MPH; Molly Brett MD, and Matthew Watto MD, FACP Cover Art: Matthew Watto MD, FACP Reviewer: Leah Witt, MD Technical Production: Pod Paste Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Show Segments Intro, guest introduction, disclaimer Cognitive safety of very low LDL Cholesterol Suzetrigine for acute pain Risk for amputation associated with SGLT2 inhibitors Transfusion strategies in acute MI with anemia revisited Outro Sponsor: Freed Visit Freed.ai and usecode: CURB50 to get $50 off your first month when you subscribe.  Sponsor: Ezeresus Listeners of the Curbsiders podcast get access to a 2-month free trial, letting them use 100% of the features of the app. For more information visit www.ezresus.com/curbsiders Sponsor: Bombas  Enjoy worldwide shipping to over two hundred countries. Head over to Bombas.com/curb and use code curb for 20% off your first purchase. Sponsor: Continuing Education Company Special offer for Curbsiders listeners: Save30% on all online courses and live webcasts with promocode CURB30. Visit www.CMEmeeting.org/curbsiders to explore all offerings and claim your discount. 

Is low blood pressure hindering your heart failure treatment? How do you balance life-saving medications with hypotension? We explore the definitions, causes, and practical solutions to optimize patient care. Learn how to navigate ARNI, beta-blockers, SGLT2 inhibitors, and MRAs effectively.

Qual é o risco de pacientes hospitalizados apresentarem cetoacidose por uso de inibidores do SGLT2?

Send us a textDive deep into the groundbreaking intersection of diabetes management and athletic performance with Phil Southerland, CEO and Co-Founder of Team Novo Nordisk, the world's first all-diabetes professional cycling team, and President of the Team Type 1 Foundation. In this powerful episode of "Know Your Physio," we explore Phil's incredible journey from a young man diagnosed with type 1 diabetes to a global advocate and elite athlete.Discover the intricate science behind insulin, glucose, and ketone metabolism, and learn how to optimize these pathways for better diabetes control. Phil shares his personal experiences with exogenous ketones and discusses cutting-edge treatments like SGLT2 inhibitors. We also delve into the latest research on pre-exercise food ingestion and reactive hypoglycemia, providing practical strategies for managing blood sugar during physical activity.Phil's innovative approach to diabetes and exercise, particularly through cycling, offers life-changing insights for anyone looking to improve their health. We discuss his global mission to educate and empower the 1.2 billion people living with diabetes, and his collaborations with the United Nations and Novo Nordisk.Hear inspiring stories from Team Novo Nordisk's races and learn how they are redefining what's possible with diabetes. Whether you're a healthcare professional, a person with diabetes, or a fitness enthusiast, this episode delivers crucial information and motivation.Links Mentioned in Today's Episode:Super SapiensTeam Type 1Not Dead Yet: My Race Against DiseaseGary Hall Junior Olympic SwimmerBioStrapBook: The Joy Of MovementPhil on TwitterPhil on LinkedInSupport the show

Qual é a relação entre a função renal e a eficácia dos inibidores do SGLT2?

Comparação entre inibidores da DPP-4 e inibidores do SGLT2 em pacientes hospitalizados.

Qual são as recomendações atuais sobre o uso de inibidores do SGLT2 em pacientes hospitalizados?

N301 - Cobertura ADA - SGLT2 e efeitos CV - Há influência na reserva de fluxo coronariano? Otávio Rizzi e Márcio Krakauer. by SBD

Die S3-Leitlinie zur Niereninsuffizienz hat ein großes Update erhalten. Im EvidenzUpdate-Podcast schauen wir mit Jean-François Chenot, was sich geändert hat. Mit Scherer als Interviewer und Nößler als Brotbäcker.

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Ralph DeFronzo is a distinguished diabetes researcher and clinician whose groundbreaking work on insulin resistance has reshaped the understanding and treatment of type 2 diabetes. In this episode, Ralph shares insights from his five decades of research, including his pivotal role in bringing metformin to the U.S. and developing SGLT2 inhibitors. Ralph explores the impacts of insulin resistance on specific organs, the pharmacologic interventions available, and the gold-standard euglycemic clamp method for measuring insulin resistance. This episode is a masterclass in the pathophysiology and treatment of type 2 diabetes, featuring an in-depth discussion of GLP-1 receptor agonists, metformin, and a lesser-known class of drugs that opened Peter's eyes to new possibilities in diabetes care. We discuss: Metabolic disease as a foundational driver of chronic illness [4:00]; Defining insulin resistance: effects on glucose, fat, and protein metabolism, and how it varies between healthy, obese, and diabetic individuals [8:15]; The historical significance of the development of the euglycemic clamp technique for measuring insulin resistance [11:45]; How insulin affects different tissues: liver, muscle, and fat cells [15:00]; The different ways insulin resistance manifests in various tissues: Alzheimer's disease, cardiovascular disease, and more [25:00]; The dangers of hyperinsulinemia, and the importance of keeping insulin levels within a physiological range [29:00]; The challenges of identifying the genetic basis of insulin resistance and type 2 diabetes [37:00]; The “ominous octet”—a more comprehensive model of type 2 diabetes than the traditional triumvirate [45:45]; The kidneys' unexpected role in worsening diabetes, and how SGLT2 inhibitors were developed to treat diabetes [55:45]; How insulin resistance in the brain and neurocircuitry dysfunction contribute to overeating and metabolic disease [1:04:15]; Lipotoxicity: how overeating fuels insulin resistance and mitochondrial dysfunction [1:07:30]; Pioglitazone: an underappreciated and misunderstood treatment for insulin resistance [1:10:15]; Metformin: debunking the misconception that it is an insulin sensitizer and explaining its true mechanism of action [1:19:15]; Treating diabetes with triple therapy vs. the ADA approach: a better path for diabetes management [1:24:00]; GLP-1 agonists, the Qatar study, and rethinking diabetes treatment [1:31:30]; Using a hyperglycemic clamp to look for genes that cause diabetes [1:45:15]; The superiority of measuring C-peptide instead of insulin to assess beta-cell function [1:46:45]; How GLP-1-induced weight loss affects muscle mass, the benefits and risks of myostatin inhibitors, and the need for better methods of evaluating functional outcomes of increased muscle mass [1:51:30]; The growing crisis of childhood obesity and challenges in treating it [2:02:15]; The environmental and neurological factors driving the obesity epidemic [2:07:30]; The role of genetics, insulin signaling defects, and lipotoxicity in insulin resistance and diabetes treatment challenges [2:11:00]; The oral glucose tolerance test (OGTT): detecting early insulin resistance and beta cell dysfunction [2:18:30]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

In this episode, Dr. Steve Edelman and Dr. Jeremy Pettus dive into a little-known but critical complication of diabetes—fatty liver disease. They are joined by Dr. Juan Pablo Frias, an endocrinologist and metabolic disease expert, to explore why people with diabetes are at significantly higher risk of developing fatty liver and what can be done to prevent, detect, and treat it before it leads to serious complications. They discuss the direct connection between insulin resistance, obesity, and liver health, the silent progression of fatty liver disease, and why liver health should be a key part of diabetes management. The episode also highlights how diabetes medications like GLP-1 receptor agonists (Ozempic, Mounjaro) and SGLT2 inhibitors may help protect the liver in addition to their benefits for blood sugar, heart, and kidney health.Key Topics:Why fatty liver disease is a major but often overlooked complication of diabetes and why doctors are just starting to take it seriously.How insulin resistance drives fat accumulation in the liver and why people with type 2 diabetes are at much higher risk.The silent progression of fatty liver disease, why most people don't have symptoms until it's too late.How fatty liver impacts blood sugar control, and why treating your liver could actually improve your diabetes management.Why people with diabetes should ask their doctors about liver screening, and how simple lab tests like FIB-4 can detect early signs of trouble.The growing connection between diabetes, heart disease, kidney disease, and fatty liver, and why experts now see them as part of the same metabolic syndrome.Can diabetes medications also treat fatty liver? The exciting potential of GLP-1s, SGLT2 inhibitors, and new liver-specific treatments like Rezdiffra.What lifestyle changes really make a difference? How weight loss, diet, and exercise can help reverse fatty liver and improve diabetes at the same time. ★ Support this podcast ★

Prós e Contras do uso de inibidores do SGLT2 em pacientes hospitalizados

In this episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, discuss a pair of recently published studies examining the use of diabetes technology in adults with type 2 diabetes. SECURE-T2D A single-arm prospective study conducted at 21 US clinical centers, SECURE-T2D assessed the impact of automated insulin delivery (AID) on glycemic control in adults with type 2 diabetes using insulin for at least 3 months. The study enrolled 305 participants (mean age, 57 years; 57% female), with a diverse racial and ethnic representation, including 24% Black and 22% Hispanic or Latino. Following a 14-day standard therapy phase, participants used the Omnipod 5 AID system for 13 weeks. HbA1c decreased from 8.2% (SD, 1.3) at baseline to 7.4% (SD, 0.9) (mean difference, -0.8 percentage points; 95% CI, -1.0 to -0.7; P

In this episode, Dr. Steve Edelman and Dr. Jeremy Pettus explore the critical connection between heart health, kidney function, and diabetes, known as the Cardiorenal Metabolic (CKM) Syndrome. They are joined by Dr. Jennifer Green, an expert in endocrinology and cardiology from Duke University, to discuss how diabetes impacts multiple organs, the latest advancements in treatment, and what individuals can do to protect their heart and kidneys. They break down why heart and kidney health should not be thought of in isolation, how specialists are now working together more than ever, and the game-changing new medications that benefit both diabetes management and overall organ health. Dr. Green also highlights the importance of patient self-advocacy, ensuring the right tests and treatments are being considered.Key Topics:What is Cardiorenal Metabolic Syndrome? How diabetes can impact the heart and kidneys over time – and what can you do to slow or prevent damage?How doctors are breaking down medical silos and specialists are working together more than ever to manage diabetes complicationsThe new era of diabetes medications – how SGLT2 inhibitors and GLP-1 receptor agonists are revolutionizing diabetes careWhy is it critical to get annual kidney function tests – and why don't many doctors routinely check for albumin in urine?How to be your own health advocate – what patients should ask their doctors to ensure they're receiving optimal care?What is the challenge of staying on long-term medications – how to frame these life-saving treatments as an ongoing investment in healthWhat's next for diabetes research and what new trials are underway, especially for those with type 1 diabetes, to see if these treatments can offer more benefits? ★ Support this podcast ★

In this episode, host Alyssa Watson, DVM, welcomes Alyssa Jenkins, DVM, to talk about her recent Clinician's Brief article, “Top 3 Recent Advances in Feline Diabetes Management.” Dr. Jenkins starts with a feline diabetes mellitus refresher, including the comparison between it and type I/type II diabetes in humans. She then details the major new things for diabetic cats: SGLT2 inhibitors, longer-acting insulins, and continuous glucose monitors.Resource:https://www.cliniciansbrief.com/article/diabetes-cats-insulin-blood-sugar-monitorContact:podcast@instinct.vetWhere To Find Us:Website: CliniciansBrief.com/PodcastsYouTube: Youtube.com/@clinicians_briefFacebook: Facebook.com/CliniciansBriefLinkedIn: LinkedIn.com/showcase/CliniciansBrief/Instagram: @Clinicians.BriefX: @CliniciansBriefThe Team:Alyssa Watson, DVM - HostAlexis Ussery - Producer & Multimedia Specialist

Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 25 minutes long and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update   discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting. Welcome to diabetes core update where every month we go over the most important articles to come out in the field of diabetes. Articles that are important for practicing clinicians to understand to stay up with the rapid changes in the field.  This issue will review: 1.     Large Language Model GPT-4 Compared to Endocrinologist Responses on Initial Choice of Antidiabetic Medication   2.     Long term health outcomes in people with diabetes 12 months after hospitalization with COVID-19 in the UK: a prospective cohort study 3.     Risk of nephrolithiasis associated with SGLT2 inhibitors versus DPP4 inhibitors among patients with type 2 diabetes: a target trial emulation study 4.     Early Screening for Latent Autoimmune Diabetes in Adults to Improve Care—Beyond the Routine 5.     Project ECHO Diabetes Trial Improves Outcomes for Medically Underserved People   For more information about each of ADA's science and medical journals, please visit Diabetesjournals.org. Hosts: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health

Welcome back to the Real Life Pharmacology podcast! We are on the home stretch of the top 200 medications. This is meant to be a quicker refresher of some of the most important drugs you'll come across in practice. Please be sure to go search the archives at RealLifePharmacology.com if you are looking for more information on one specific medication. We have over 300 individual episodes on specific drugs! On this episode of the Top 200 medications, we've covered the medications below. Niaspan (niacin) is vitamin B3 and may be used in patients who fail other therapies for triglyceride management. Uroxatral (alfuzosin) is a selective alpha-blocker that can be helpful in relieving urinary retention symptoms in BPH. Biaxin (clarithromycin) is a macrolide antibiotic that is notorious for many drug interactions because it inhibits CYP3A4. Zomig (zolmitriptan) is a "triptan" medication that can be used for the acute relief of migraine headaches. Invokana (canagliflozin) was one of the first SGLT2 inhibitors invented that can be used to lower blood sugar in type 2 diabetes.

$5 Q-BANK: https://patreon.com/highyieldfamilymedicine Intro 0:30, Diagnostic criteria 2:02, Type 1 vs type 2 diabetes 5:43, Metformin 6:57, Sulfonylureas 8:36, TZDs 9:09, DPP-4 inhibitors 9:54, GLP-1 agonists 10:39, SGLT2 inhibitors 12:39, Insulin 14:08, Diabetic ketoacidosis (DKA) 16:32, Hyperglycemic hyperosmolar syndrome (HHS) 23:07, Microvascular complications 25:06, Macrovascular complications 33:07, Practice questions 34:46

Get My Book On Amazon: https://a.co/d/avbaV48Download The Peptide Cheat Sheet: https://peptidecheatsheet.carrd.co/

Too busy to read the Lens? Listen to our weekly summary here! In this week's episode we discuss Delayed repair of open globe injuries between 25-36 hours may be reasonable without significantly increasing risks of endophthalmitis or poor visual outcomes. SGLT2 inhibitors may reduce progression from non-proliferative to proliferative diabetic retinopathy (PDR) in patients with pre-existing NPDR, though it does not affect development of NPDR in those without prior DR. The Ocular Hypertension Treatment Study (OHTS) found that visual field loss accelerates significantly after primary open-angle glaucoma diagnosis, with progression linked to older age, higher cup-to-disc ratios, and greater IOP variability. Anti-VEGF injections for retinal diseases cause significant short-term IOP spikes that tend to normalize within 15 minutes.

We're taking a short winter break, but we'll be back with new shows in time for Christmas and New Years! Can't wait for more new episodes? Sign up for our Patreon with 15% off an annual membership at patreon.com/curbsiders (https://www.patreon.com/c/curbsiders) and get instant access to 40 plus bonus episodes! Step up your diabetes game! Learn the ins and outs of continuous glucose monitors (CGM) including key features, what and how to order, interpreting CGM data (time in range, time above range, etc.), and how to make adjustments to a patient's insulin regimen, aka “insulin pattern matching”. We discuss common scenarios including overnight hypoglycemia, exercise-induced hypoglycemia, post-prandial hyperglycemia, what to do when the patient runs high all the time, and how to incorporate GLP1 agonists and SGLT2 inhibitors into a patient's regimen. Returning guest and Paul's favorite frenemy, Dr. Jeff Colburn (VCU Health) returns! Visit our website for detailed show notes for this episode. Claim free CME for this episode at curbsiders.vcuhealth.org! Sponsor: Freed You can try Freed for free right now by going to freed.ai. And listeners of Curbsiders can use code CURB50 for $50 off their first month. Sponsor: OpenEvidence If you haven't tried it out yet check it out, it will save you time and help you make better decisions go to openevidence.com/curbsiders Sponsor: Panacea Legal Physicians deserve to be informed of the risks and benefits of their employment contract. Let Panacea Legal help you today at Panacea.Legal

Welcome to Protecting Your Nest with Dr. Tony Hampton. In this episode of Protecting Your NEST, Dr. David Ahn, Chief of Diabetes Services at Hoag and creator behind TikTok's @diabetesdoc, dives into the realities of managing and reversing diabetes. We discuss the role of low-carb and ketogenic diets, cutting-edge diabetes technologies, and the steps to achieving remission for type 2 diabetes. Dr. Ahn shares his expertise on empowering patients and debunking common myths about diabetes care. In this discussion, Drs. Tony and David talk about: (02:34) What led Dr. Ahn to study endocrinology and, in particular, diabetes (06:36) What Dr. Ahn does in his role as Chief of Diabetes Services at his healthcare system, Hoag (09:07) Dr. Ahn's perspective on keto, low-carb, and carnivore as lifestyle interventions for diabetes patients (13:18) Using terms like ‘remission' and ‘reversal' when referring to diabetes (19:04) How Dr. Ahn incorporates CGMs into his patient care (23:06) Dangerous diabes myths (27:54) GLP1 and SGLT2 drugs and the risks/benefits of each (32:06) Lifestyle versus pharmaceutical interventions for treating diabetes (38:00) The emotional/relational aspects of treating metabolic disfunction and how doctors can use a tactful approach to help their patients reclaim their health in the midst of hard personal circumstances (44:53) A particularly interesting ketogenic patient success story (47:51) The U.S. Dietary Guidelines and ADA Guidelines (55:32) How Dr. Ahn uses TikTok to share information about diabetes Thank you for listening to Protecting Your Nest. For additional resources and information, please see the links below.   Links:   Dr. David Ahn: Instagram X Linktree TikTok Hoag Diabetes Center   Dr. Tony Hampton: Linktree Instagram Account LinkedIn Account Ritmos Negros Podcast Q Med Symposium for Metabolic Health Lectures How Waking Up Every Day at 4:30 Can Change Your Life Keto Mojo

When a new drug class enters the veterinary world, first comes the excitement…then comes the learning. In this episode of Clinician's Brief Partner Podcast, Jocelyn Mott, DVM, DACVIM, answers your most frequently asked questions when it comes to using a novel drug class in the treatment of feline diabetes mellitus: the sodium-glucose cotransporter-2 inhibitor. Tune in as she explains when, how, and why to consider this option in newly diagnosed feline diabetics.Sponsored by ElancoResource:https://my.elanco.com/us/bexacatContact us:Podcast@briefmedia.comWhere to find us:Cliniciansbrief.com/podcastsFacebook.com/clinciansbriefTwitter: @cliniciansbriefInstagram: @clinicians.briefThe Team:Beth Molleson, DVM - HostTaylor Argo - Producer & Project Manager, Brief StudioRandall Stupka - Podcast Production & Sound Editing

In this podcast, a study from Ontario revealed that SGLT2 inhibitors, when combined with statins, were associated with a 25% lower risk of rhabdomyolysis compared to DPP4 inhibitors. A phase I trial at Washington University demonstrated promising outcomes for a neoantigen DNA vaccine aimed at preventing recurrence in triple-negative breast cancer (TNBC). Finally, intensive systolic blood pressure control in Chinese patients with type 2 diabetes and elevated cardiovascular risk significantly reduced major cardiovascular events compared to standard care.

“It's about symptoms and how you're doing and how you're feeling. It's not necessarily the number on the lab tests,” says Amy Killen, M.D. Amy Killen, M.D., a leading anti-aging and regenerative physician, joins us today to discuss science-backed methods to improve longevity, including stem cell therapies, hormone replacement, and more:  - Women's longevity stack (~2:00) - Hormone health (~4:40) - Hormone replacement therapy (HRT) (~6:05) - Different types of HRT (~7:37) - Killen's story (~9:07) - Stem cell therapy (~11:01) - Sexual health and stem cells (~17:00) - Nitric oxide (~18:10) - How to measure nitric oxide levels (~20:25) - Collagen and hyaluronic acid (~22:30) - Red light and PEMF (~23:36) - Killen's daily routine (~25:15) - Overrated practices in wellness culture (~26:29) - Modern medicine for longevity benefits (~29:45) - Testosterone replacement therapy (TRT) for men (~33:20) - Popular therapies and treatments (~36:40) - The future of longevity and women's health (~42:32) Referenced in the episode:  - Keep up with her @Dr.AmyBKillen (IG, FB, TikTok) - Follow her online (www.dramykillen.com)  - Check out her company (https://hopbox.life/)  - Learn more about her clinic (www.humanauthealth.com)   - Listen to Stacy Sims, Ph.D. on the mbg podcast episode #514  - Research on SGLT2 inhibitors (https://doi.org/10.1016/j.pcad.2023.10.003)  - Research on PCSK9 inhibitors (https://doi.org/10.1016/j.ajpc.2024.100701)  immy is a natural, effective solution to retune your immune system, while addressing inflammatory status and improving mental health and overall resilience.* Learn more about immy today at immy.co. *These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. ​We hope you enjoy this episode, and feel free to watch the full video on YouTube! Whether it's an article or podcast, we want to know what we can do to help here at mindbodygreen. Let us know at: podcast@mindbodygreen.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

Despite advances in the management of acute myocardial infarction (MI), up to 38% of patients will experience signs of heart failure (HF) and many have a reduced left ventricular ejection fraction (LVEF). Sodium-glucose cotransporter 2 (SGLT2) inhibitors have well-documented cardiovascular benefits. However, data are limited regarding their use after an acute MI. Guest Authors: Amy Hu, PharmD and Kathleen Pincus, PharmD, BCPS, BCACP, CDCES Music by Good Talk

In this episode, Dr. Valentin Fuster discusses groundbreaking research on SGLT2 inhibitors and their impact on heart failure, highlighting the validation of mechanistic proteomic signatures from a major clinical trial. The study reveals how empagliflozin influences over 2,000 proteins, promoting autophagy, enhancing mitochondrial health, and normalizing kidney function, offering new insights into therapeutic strategies for heart failure management.

In this episode, Dr. Valentin Fuster highlights the groundbreaking studies featured in the November 12, 2024 issue of the JACC, focusing on the emerging role of proteomics in understanding heart failure and hypertrophic cardiomyopathy. He discusses key findings on SGLT2 inhibitors, the efficacy of complete revascularization in myocardial infarction patients, and novel treatments for hypercholesterolemia, emphasizing the transformative potential of these insights for cardiovascular care.

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: iPhone control for Omnipod 5 rolls out, Libre is approved for use in CT scans and MRIs, Dexcom files for 15 day wear, Luna nighttime pump goes to trial, iLet cell trials move forward and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Insulet Corporation announces the full market release of the Omnipod 5 App for iPhone® in the U.S. App allows users to fully control their Omnipod 5 Automated Insulin Delivery System (Omnipod 5) from their compatible iPhone1. For example, users can bolus for a meal, change a Pod, and adjust settings. Importantly, this also means that Omnipod 5 users who have a compatible iPhone no longer need to carry a separate Controller to help manage their insulin delivery requirements. Insulet says that the App for iPhone has been the number one feature requested by Omnipod 5 users. The Omnipod 5 App for iPhone is currently compatible with the Dexcom G6 Continuous Glucose Monitoring (CGM) System and is expected to be compatible with the Dexcom G7 CGM in the U.S. in 2025. The Omnipod 5 App for Android phones is also available to U.S. customers. https://www.businesswire.com/news/home/20241029838744/en/Omnipod%C2%AE-5-App-for-iPhone%C2%AE-Now-Fully-Available-in-the-United-States   XX Th FDA says it's okay to keep on your FreeStyle Libre 2 and 3 for procedures like X-rays, CT scans and MRIs. Abbott said it makes its systems the first and only patient-applied CGM sensors approved for these screenings. Imaging procedures often come as part of diabetes care, Abbott said, especially as diabetes can cause a number of medical complications. The company rigorously tested its Libre 2 and 3 sensors to ensure they remain effective after radiologic procedures. This FDA clearance comes with no changes made to the sensor.   https://www.drugdeliverybusiness.com/fda-approves-abbott-cgms-medical-imaging/ XX Tidepool announced a new data integration with Abbott for the company's FreeStyle Libre continuous glucose monitors (CGMs). The companies aim to deliver cloud-to-cloud integration for an automatic stream of data from patients using Abbott's CGMs in the U.S. Data streams to Tidepool+, a diabetes data visualization and population health platform. Tidepool+ provides intuitive tracking and visualization of diabetes data to make the data informative and actionable for clinicians, people with diabetes and caregivers. https://www.drugdeliverybusiness.com/tidepool-abbott-data-integration-freestyle-libre/ XX Beta Bionics announced today that it launched the integration of the iLet bionic pancreas with the Abbott (NYSE:ABT) FreeStyle Libre 3 Plus. The companies announced their plan to combine the FreeStyle Libre 3 Plus continuous glucose monitor (CGM) with iLet last month. According to Beta Bionics, this makes iLet the first available automated insulin delivery (AID) system to integrate with Libre 3 Plus in the U.S. iLet users can now update their app and software to gain a choice of integrated CGMs. They can choose between Libre 3 Plus and Dexcom CGMs.   Abbott, meanwhile, continues to push forward on the automated insulin delivery integration front. The company recently paired its FreeStyle Libre 2 Plus with Insulet's Omnipod 5 in Europe. It also announced compatibility with the Tandem Diabetes Care t:slim X2 system in January.   Notably, the company also struck a deal with Medtronic in August. They aim to develop CGMs specifically for the medtech giant's own insulin delivery systems. https://www.drugdeliverybusiness.com/beta-bionics-launches-ilet-abbott-libre/ XX Dexcom is asking the FDA to approve the G7 CGM for 15 days. Right now the G7 has a 10 day wear time.  Dexcom also launched the G7 CGM in Australia and rolled out Dexcom ONE+ in France. Some front-office news.. EVP and CCO Teri Lawver plans to retire at the end of the year. https://www.drugdeliverybusiness.com/dexcom-submits-15-day-cgm-fda-q3-2024/ XX Stelo by Dexcom is one of TIME's Best Inventions of 2024! As the first glucose biosensor available in the U.S. without a prescription, Stelo has unlocked our industry-leading technology for millions of people across the U.S. looking to improve their health through personalized insights. We're honored to be recognized among other unique innovations in the Home Health category that support people's health. https://time.com/7094684/dexcom-stelo/   XX   Luna Diabetes is moving forward with a pivotal trial evaluating its automated closed-loop insulin technology, the Luna System. This is designed to address nighttime glucose control for insulin pen users. It's meant for use only during sleep - Luna system was developed as a wearable insulin pump and alternative to insulin pen to automate the insulin delivery process. The device works with continuous glucose monitors (CGM) to calculate and deliver rapid-acting insulin doses during sleep. Luna Diabetes expects the study to be completed early next year, with plans to commercially launch the device “soon after”.   https://finance.yahoo.com/news/luna-diabetes-trials-automated-wearable-115211566.html?guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAJIrWwjdye-ehrLNDt-LIGb5qTXaKDTIa8NWwiT7fKwFFgjDMN2nnINis6YfFePWP2ZA2DVYWXEIZQqRlQ4aKLFrYWgvw1jdI-t1n9kO6NIzdBCMXQNNCVl_S-75lDNip2SysHDJQmyqSc4wLjfDya3v9wwTWU-KgE_OqrPCTnlu XX Researchers are urging  caution when prescribing off-label glucose-lowering drugs to individuals with type 1 diabetes (T1D) while acknowledging that doctors keep prescribing them because they seem to work so well. Both glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown significant benefits for cardiovascular and renal health in other populations, particularly in patients with type 2 diabetes.   SGLT2 inhibitors carry a significant risk of euglycemic diabetic ketoacidosis, a dangerous condition most common in T1D individuals where toxic levels of blood acidification can occur. Due to this risk, SGLT2 inhibitors were removed for T1D use in Europe, and the U.S. Food and Drug Administration (FDA) has not approved them for T1D.   For GLP-1RAs, there are concerns about substantial weight loss potentially leading to ketoacidosis or worsening hypoglycemia. While these medications can be beneficial in managing weight, the extent of that weight loss can create new problems in people with T1D as their insulin needs may quickly change as a result. Prescribing in People With Type 1 Diabetes," published in JAMA, the authors stress the critical need for more research to confidently allow the off-label usage of potentially dangerous secondary treatments. The data suggests clinicians are turning to these treatments to manage cardiovascular and renal complications in T1D patients, even though the drugs are not explicitly approved for this condition.   Conversely, those newly prescribed GLP-1RAs had higher rates of obesity (69.4% vs. 45.7%). This data indicates that clinicians are prescribing GLP-1RAs to help manage obesity in T1D patients, as weight management is a critical component of diabetes care.   The percentage of the T1D population prescribed GLP-1RAs increased significantly, from 0.3% in 2010 to 6.6% by 2023. The percentage prescribed SGLT2 inhibitors rose from 0.1% in 2013 to 2.4% by 2023. Overall, the percentage of T1D patients prescribed either of these medications increased from 0.7% to 8.3% during this period.     Results of the study suggest that despite regulatory concerns, off-label use of GLP-1RAs and SGLT2 inhibitors in T1D continues to grow primarily due to their cardiorenal and weight management benefits.   "Prospective studies on the efficacy and safety of GLP-1RAs or SGLT2 inhibitors in the T1D population are needed," the Research Letter concludes, "Before such evidence becomes available, caution should be exercised when prescribing these treatments to individuals with T1D."   https://medicalxpress.com/news/2024-10-glucose-lowering-drugs-diabetes-patients.html XX More good islet transplant news.. from Eledon Pharmaceuticals and University of Chicago. These are potentially the first human cases of insulin independence achieved using a transplant of insulin-producing islet cells in combination with its experimental immunosuppressant drug. The first two subjects achieved insulin independence and normal hemoglobin A1C (HbA1c) levels, a measure of average blood glucose, post-transplant. The third subject, who recently received an islet transplant, decreased insulin use by more than 60% three days following the procedure and continues on an insulin independence trajectory. Some of the funding for this study comes from Breakthrough T1D. https://www.globenewswire.com/news-release/2024/10/29/2970713/0/en/Eledon-Pharmaceuticals-Announces-Positive-Initial-Data-from-Subjects-with-Type-1-Diabetes-Treated-with-Tegoprubart-as-Part-of-an-Immunosuppression-Regimen-Following-Islet-Transplan.html XX   Semaglutide may reduce Alzheimer's risk in type 2 diabetes patients, with research suggesting significant protective benefits compared to other diabetes drugs. published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association, the study suggests that T2D patients taking semaglutide had a significantly lower risk of developing Alzheimer's. This effect was observed consistently across various subgroups, including differences in obesity status, gender, and age. Semaglutide, which acts on glucagon-like peptide receptors (GLP-1R) to curb hunger and regulate blood sugar in T2D, is also the active component in the diabetes and weight-loss drugs Wegovy and Ozempic. About 120,000 Americans die from Alzheimer's disease each year, with the disease listed as the seventh-leading cause of death nationally, according to the CDC. https://scitechdaily.com/alzheimers-breakthrough-popular-diabetes-drug-ozempic-linked-to-much-lower-risk/ XX   XX Edgepark commercial XX Apple's non invasive blood glucose monitoring rumors are back. But this sounds like just software.. no watch or hardware. According to the report, Apple doesn't currently have plans to release the app, but may integrate the technology into its future health products. The app could reportedly show consumers how certain foods impact their blood sugar levels, based on measurements taken by existing blood sugar monitoring devices. One report says apple is exploring uses for blood sugar data and what tools they could create for consumers as a result. Latterly, he reports testing on the app has been paused, but says the tests could pave the way for better food tracking on Apple's own health software or better third-party glucose tracking integration. https://www.techradar.com/health-fitness/apple-is-testing-a-new-blood-sugar-product-but-its-not-the-apple-watch-update-weve-been-waiting-for XX And finally, it's diabetes awareness month. Please follow on social – I'll be doing a few things but mostly I think this month is great to educate the general public.. every month is diabetes month for this community. XX Join us again soon!

Send us a textUnlock the future of feline health with our special guest, Dr. Ellen Behrend, as she unveils the transformative potential of SGLT2 inhibitors for cats navigating the challenges of diabetes mellitus. She focuses on velagliflozin, a once-daily liquid oral SGLT2 inhibitor and brings her passion for endocrinology to the forefront, sharing her insights into this groundbreaking treatment originally successful in human type 2 diabetes. Join us as we dive into this new era of easier diabetes management for your feline friends. In our engaging discussion, we venture into the evolving landscape of diabetes care in pets, spotlighting novel treatments and their unexpected benefits for renal and cardiac health in cats. Ellen's personal anecdotes underscore the value of critical thinking and mentorship within veterinary studies, while we demystify common misconceptions about SGLT2 inhibitors, particularly diabetic ketoacidosis risks. Don't miss Ellen's article in JAVMA and join us next week for more insightful conversations. Please remember to rate and review us on your favorite podcast platform!JAVMA open access article: https://doi.org/10.2460/javma.24.03.0174INTERESTED IN SUBMITTING YOUR MANUSCRIPT TO JAVMA ® OR AJVR ® ? JAVMA ® : https://avma.org/JAVMAAuthors AJVR ® : https://avma.org/AJVRAuthorsFOLLOW US:JAVMA ® : Facebook: Journal of the American Veterinary Medical Association - JAVMA | Facebook Instagram: JAVMA (@avma_javma) • Instagram photos and videos Twitter: JAVMA (@AVMAJAVMA) / Twitter AJVR ® : Facebook: American Journal of Veterinary Research - AJVR | Facebook Instagram: AJVR (@ajvroa) • Instagram photos and videos Twitter: AJVR (@AJVROA) / Twitter JAVMA ® and AJVR ® LinkedIn: https://linkedin.com/company/avma-journals

When treating heart failure, how do we distinguish between the expanding list of medications recommended for “Guideline Directed Medical Therapy” (GDMT) and what might be considered runaway polypharmacy? In this week's podcast, we'll tackle this crucial question, thanks to a fantastic suggestion from GeriPal listener Matthew Shuster, who will join us as a guest host. We've also invited two amazing cardiologists, Parag Goyal and Nicole Superville, to join us about GDMT in heart failure with reduced ejection fraction (HFrEF) and in Heart Failure with preserved EF (HFpEF).  We talk about what is heart failure, particularly HFpEF, how we treat it (including the use of sodium–glucose cotransporter-2 inhibitors (SGLT2's), and how we should apply guidelines to individual patients, especially those with multimorbidity who are taking a lot of other medications. I'd also like to give a shout out to a recent ACP article on HFpEF with an outstanding contribution from Ariela Orkaby, geriatrician extraordinaire (we also just did a podcast with her on frailty).  

Welcome to my podcast. I am Doctor Warrick Bishop, and I want to help you to live as well as possible for as long as possible. I'm a practising cardiologist, best-selling author, keynote speaker, and the creator of The Healthy Heart Network. I have over 20 years as a specialist cardiologist and a private practice of over 10,000 patients. Dr. Warrick Bishop, a cardiologist and CEO of the Healthy Heart Network, discusses key insights from a recent cardio metabolic health conference he attended. He covers topics like the similar cardiovascular disease risk for type 1 and type 2 diabetics, the benefits of newer diabetes medications like SGLT2 inhibitors and GLP-1 agonists beyond glucose control, the importance of managing conditions like fatty liver disease and PCOS to prevent cardiometabolic issues, and the links between metabolic health, inflammation, and cognitive decline. He emphasizes the interconnected nature of heart health, diabetes, fatty liver, and brain function, and encourages listeners to be proactive about monitoring and managing their cardiometabolic health through lifestyle, medication, and regular check-ups.

Claim your complimentary gift of my exclusive mini weight care guide today!Link: Weight Care Guide — Dr. Francavilla Show (thedrfrancavillashow.com)The multifaceted world of type 2 diabetes can sometimes be hard to comprehend. In this episode, I'm joined by Dr. Lindsay Ogle, a family practice physician based in Missouri. She specializes in metabolic care, weight loss, and obesity through virtual telehealth services, focusing on treating and preventing conditions like diabetes, prediabetes, PCOS, fatty liver disease, high cholesterol, metabolic syndrome, and obesity.Dr. Ogle and I delve into important topics related to type 2 diabetes, such as understanding treatment options, lifestyle changes, and other key insights.This episode answers critical questions like:Why is it important to treat diabetes early?What is the connection between diabetes and weight management?Why are new medications like GLP-1 agonists and SGLT2 inhibitors beneficial for both diabetes and weight control?Can patients on insulin transition to these new medications?Who are the candidates for bariatric surgery?Tune in to hear the full discussion and discover how the latest developments in diabetes care could impact individual health.Connect with Dr. Ogle:Instagram: dr.lindsayogleFacebook: Lindsay Ogle Website: Missouri Metabolic HealthYoutube: Dr. Lindsay Ogle - Family & Obesity MedicineConnect with me:Instagram: doctorfrancavillaFacebook: Help Your Patients Lose Weight with Dr. FrancavillaWebsite: Dr. Francavilla ShowYoutube: The Doctor Francavilla ShowGLP Strong: glpstrong.com 

This episode is sponsored by Freed – Freed is an amazing time saver for busy healthcare professionals! It listens, transcribes, and writes medical notes for you! Go check them out and support our sponsor! Robitussin (Guaifenesin) is a medication that is used as a cough suppressant. It is often combined with numerous other medications so patients need to pay attention Valium (diazepam) is a benzodiazepine used to treat anxiety or seizures. Falls, dizziness, confusion, and sedation are common adverse effects. Viagra (sildenafil) makes the list at number 73. This medication is a PDE-5 inhibitor that can be used for erectile dysfunction. Bactroban (mupirocin) is a topical antibiotic that can be used for superficial skin infections. Januvia (Sitagliptin) is a DPP4 inhibitor used for treating hyperglycemia in type 2 diabetes. It doesn't reduce A1C quite as much as other diabetes medications like SGLT2 inhibitors and GLP-1 agonists.

Chronic Kidney Disease (CKD) is a serious complication of diabetes that often goes unnoticed in its early stages. In this episode of the Taking Control of Your Diabetes podcast, hosts Dr. Jeremy Pettus and Dr. Steve Edelman, both endocrinologists living with type 1 diabetes, provide an in-depth exploration of CKD in diabetes. They discuss the prevalence, screening methods, and latest treatment options for diabetic kidney disease, focusing on type 1 diabetes. Dr. Edelman also shares his personal experience managing CKD.In this episode, we will talk about:The prevalence and impact of kidney disease in type 1 diabetesHow diabetes affects kidney functionScreening tests for diabetic kidney disease: eGFR and UACRUnderstanding the stages of chronic kidney diseaseThe ABCs of diabetes management for kidney health: A1C, Blood pressure, and CholesterolLifestyle factors in preventing and managing kidney diseaseMedications to use and avoid with kidney diseaseThe role of ACE inhibitors and SGLT2 inhibitors in kidney protectionChallenges and considerations for people with type 1 diabetes regarding new kidney treatmentsDr. Steve Edelman's personal journey with CKDThe importance of proactive management and regular monitoring ★ Support this podcast ★

In the September 17, 2024 issue of JACC, Valentin Fuster discusses a study on sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, which shows modest improvements in health status among patients with worsening heart failure. While the study highlights sotagliflozin's benefits, it also points out gaps in understanding its full impact and emphasizes the need to optimize current treatments and explore future interventions.

Send us a Text Message.In part two of our Truth on Diabetes series, you will understand diabetes treatments as we sit down with Dr. Arpeta Gupta to dissect the latest guidelines and the transformative impact of newer diabetes medications. We will discuss how SGLT2 inhibitors and GLP-1 agonists are not only enhancing glycemic control but also delivering critical cardiovascular and renal benefits. We revisit the troubled history of TZD drugs like Avandia and contrast it with the safety profiles of today's leading medications. Drs. Gupta and Koren dive into the complexities of managing diabetes care across multiple specialties and share actionable strategies to improve interdisciplinary communication for better patient outcomes.Navigating the hurdles of diabetes treatment access is no small feat, and we tackle this issue head-on by examining how insurance policies and cost barriers affect patient care. From the implications of prior authorization and step therapy to the financial strain on patients, particularly those on federal plans, we leave no stone unturned. We also explore the exciting potential of federal drug price negotiations and recent strides in lowering insulin costs. The significance of selecting therapies that safeguard end organs and the advantages of participating in clinical trials for cutting-edge treatments are underscored, ensuring you leave with a comprehensive view of the future landscape of diabetes care.Koren's Key Three Takeaways:Guidelines and Effectiveness of Diabetes DrugsDiabetes treatment access and insuranceChallenges and Future of Diabetes TreatmentRecording Date: June 19, 2024Be a part of advancing science by participating in clinical research.Share with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramTwitterLinkedInWant to learn more checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

In the September 3, 2024, JACC issue, a major study evaluates the cardiovascular outcomes of second-line antihyperglycemic agents in type 2 diabetes, comparing SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas. The research reveals that SGLT2 inhibitors and GLP-1 receptor agonists offer superior cardiovascular protection over the other agents, highlighting their importance for patients with cardiovascular conditions.

In this episode, Dr. Valentin Fuster reviews five pivotal studies from September 2024, focusing on antithrombotic strategies and diabetes treatments. Key insights include the efficacy of dual antithrombotic therapy over triple therapy, the benefits of anticoagulation alone post-left atrial appendage occlusion, and the superior cardiovascular outcomes of SGLT2 inhibitors and GLP-1 receptor agonists in diabetes management.

Diuretic therapy in HFrEF, AF ablation, TACT 2 and the story of subgroups, and SGLT2 inhibitor underuse are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. Diuretic Therapy in HF Dapa vs Metolazone Trial https://doi.org/10.1093/eurheartj/ehad341 ADVOR https://www.nejm.org/doi/10.1056/NEJMoa2203094 II. Rapid Medication Titration for Acute HF ACC Decision Pathway https://www.jacc.org/doi/10.1016/j.jacc.2024.06.002 III. SGLT2 Inhibitor Use in the US Shin and Colleagues; JACC  https://www.sciencedirect.com/science/article/abs/pii/S0735109724076332 Editorial  https://doi.org/10.1016/j.jacc.2024.07.001 IV. AF Ablation: General Anesthesia vs Conscious Sedation Da Riis-Vestergaard and Colleagues  https://doi.org/10.1093/europace/euae203 V. TACT 2 Published TACT 1 https://jamanetwork.com/journals/jama/fullarticle/1672238 TACT 1 DM https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.113.000663 TACT 2 https://jamanetwork.com/journals/jama/fullarticle/2822472 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

The draft order:Sophia AmbrusoNayan AroraSwapnil HiremathAC GomezJoel TopfEditor Nayan AroraShow NotesPrevious drafts:2021 KDIGO Hypertension —Joel, Sophia, Swap, Nayan, Josh2021 ASN Kidney Week Draft—Joel, Sophia, Swap, Nayan, Jennie2022 The ISPD Peritonitis Guideline— Joel, Sophia, Swap, Nayan2022 ASN Kidney Week Draft—Joel, Sophia, Swap, Nayan2023 ASN Kidney Week Draft—Joel, Sophia, Swap, Nayan, AC, Josh2024 KDIGO CKD Clinical Practice Guideline —Joel, Sophia, Swap, Nayan, Josh, ACThe guidelineThe NephJC discussion Part 1 | Part 2First RoundSophia's Pick 3.7.1 We recommend treating patients with type 2 diabetes (T2D), CKD, and an eGFR ≥20 ml/min per 1.73 m2 with an SGLT2i (1A).Not Nayan's Pick 3.7.3: We suggest treating adults with eGFR 20 to 45 ml/min per 1.73 m2 with urine ACR

CardioNerds (Drs. Gurleen Kaur and Richard Ferraro) and episode FIT Lead Dr. Saahil Jumkhawala (Cardiology Fellow at the University of Miami) discuss SGLT inhibitors, focusing on the biology of SGLT and its inhibition, with Dr. Katherine Tuttle (Executive Director for Research at Providence Healthcare, Co-Principal Investigator of the Institute of Translational Health Sciences, and Professor of Medicine at the University of Washington).  Show notes were drafted by Dr. Saahil Jumkhawala. The episode audio was engineered by CardioNerds intern Christiana Dangas. This episode was produced in collaboration with the American Society of Preventive Cardiology (ASPC) with independent medical education grant support from Lexicon Pharmaceuticals. CardioNerds Prevention PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls - The Biology of SGLT Inhibition with Dr. Katherine Tuttle SGLT inhibitors, while initially developed as antidiabetic medications, have been shown to be beneficial for cardiovascular and renal outcomes. These benefits result from their on-target glucosuric effects and additional off-target effects. The side effect profiles of SGLTis are primarily mediated by glucose reabsorption in their target tissues. The side effect profile of SGLTis must be considered when prescribing these medications and is generally favorable for SGLT2is versus SGLT1is. Once SGLTis are prescribed, patients should be given specific attention to their eGFR, serum potassium, and clinical evaluations of volume status and blood pressure. Strategies to increase implementation of and reduce clinical inertia for these important class of medication remain an area of active investigation Show notes - The Biology of SGLT Inhibition with Dr. Katherine Tuttle What should prompt consideration of starting an SGLT inhibitor? Considerations for SGLT inhibitor initiation are based on a history of heart failure, kidney disease, and diabetes status. In the EMPA-KIDNEY trial, empagliflozin improved cardiovascular and kidney outcomes in those with low GFR (regardless of level of albuminuria). What is the mechanism of action of SGLT2 inhibitors? SGLT2 inhibitors improve glycemic control by blocking SGLT2 receptor-mediated reabsorption of glucose in the proximal convoluted tubule, where 80-90% of this reuptake occurs, and increased downstream excretion of glucose and sodium chloride. SGLT2 inhibitors provide only a modest glucose-lowering effect, particularly for patients with GFR

Many patients with type 2 diabetes take oral antidiabetic medications, either as monotherapy or in conjunction with other oral antidiabetic medications or insulin. It's important you are able to recognize these medications as their use increases the risk of hypoglycemia, especially when taken with insulin.  This episode provides a brief overview of each of the oral antidiabetic medications with a few key things to know about each one. Sulfonylureas (ex: glipizide) Biguanides (ex: metformin) Thiazolidinediones (ex: pioglitazone/Actos) Meglitinides (ex: repaglinide) DPP-4 inhibitors (ex: sitagliptin/Januvia) Alpha-glucosidase inhibitors (ex: acarbose) SGLT2 inhibitors (ex: canagliflozin/Invokana) Dopamine agonist (ex: bromocriptine/Cycloset) ___________________ Full Transcript - Read the article and view references FREE CLASS - If all you've heard are nursing school horror stories, then you need this class! Join me in this on-demand session where I dispel all those nursing school myths and show you that YES...you can thrive in nursing school without it taking over your life! Fast Pharmacology - Learn pharmacology concepts in 5 minutes or less in this audio based program. Perfect for on-the-go review! Pharmacology Success Pack - Want to get a head start on pharmacology? Download the FREE Pharmacology Success Pack. Clinical Success Pack - One of the best ways to fast-track your clinical learning is having the right tools. This pack includes report sheets, sheets to help you plan your day, a clinical debrief form, and a patient safety cheat sheet.

Step up your diabetes game! Learn the ins and outs of continuous glucose monitors (CGM) including key features, what and how to order, interpreting CGM data (time in range, time above range, etc.), and how to make adjustments to a patient's insulin regimen, aka “insulin pattern matching”. We discuss common scenarios including overnight hypoglycemia, exercise-induced hypoglycemia, post-prandial hyperglycemia, what to do when the patient runs high all the time, and how to incorporate GLP1 agonists and SGLT2 inhibitors into a patient's regimen. Returning guest and Paul's favorite frenemy, Dr. Jeff Colburn (VCU Health) returns! Claim CME for this episode at curbsiders.vcuhealth.org! Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Show Segments 00:00 Introduction and Diabetes Puns 01:00 Introduction of Guest and Topic 09:12 Qualifications and Eligibility for CGMs 11:32 Types of CGMs and Sensor Placement 24:47 Interpreting CGM Data and Alarms 34:30 Troubleshooting Patterns and Adjustments 35:23 Understanding Hypoglycemia and Counter Regulatory Hormone Responses 36:15 The Rule of 15 and Addressing Hypoglycemia 37:10 Reducing Basal Insulin to Address Nocturnal Hypoglycemia 38:29 Addressing Postprandial Highs with GLP-1, SGLT-2 Inhibitors, or Prandial Insulin 39:51 Managing Exercise-Induced Hypoglycemia 41:43 Preventing Exercise-Induced Hypoglycemia with Snacks 43:42 Managing Nocturnal Hypoglycemia with Sulfonylureas 45:31 Addressing Postprandial Hyperglycemia with GLP-1, SGLT-2 Inhibitors, or Prandial Insulin 46:54 Adjusting Basal Insulin to Address Morning Hyperglycemia 51:18 Troubleshooting High Blood Sugars with Basal Insulin and Mealtime Insulin 56:49 Managing High Blood Sugars with Basal Insulin and Mealtime Insulin 57:44 Addressing Adherence and Medication Barriers 59:39 Using Continuous Glucose Monitors (CGMs) for Diabetes Management 01:02:30 Using Sulfonylureas and Basal Insulin Combination as a Stopgap 01:05:49 Considering Patient Adherence and Barriers to Treatment Credits Writer and Producer: Matthew Watto MD, FACP Show Notes: Matthew Watto MD, FACP Cover Art and Infographic: Matthew Watto MD, FACP Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP    Reviewer: Emi Okamoto MD Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Guest: Jeff Colburn MD Sponsor: Freed You can try Freed for free right now by going to freed.ai. And listeners of Curbsiders can use code CURB50 for $50 off their first month. Sponsor: Panacea Financial Download the 2024 Residents & Fellows Survey Report for free at panaceafinancial.com/report.